PolyPid (NASDAQ:PYPD) Posts Earnings Results, Misses Estimates By $0.23 EPS

PolyPid (NASDAQ:PYPD) announced its quarterly earnings data on Wednesday. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23), Zacks reports.

PolyPid Trading Up 3.7 %

Shares of NASDAQ:PYPD traded up $0.11 during trading on Friday, reaching $2.94. 3,906 shares of the company traded hands, compared to its average volume of 21,450. The business’s fifty day moving average is $3.02 and its 200-day moving average is $3.32. PolyPid has a 52-week low of $2.37 and a 52-week high of $6.58. The firm has a market capitalization of $29.91 million, a price-to-earnings ratio of -0.38 and a beta of 1.32. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Wall Street Analyst Weigh In

A number of analysts have commented on PYPD shares. Rodman & Renshaw started coverage on PolyPid in a report on Tuesday, January 28th. They set a “buy” rating and a $13.00 price objective for the company. RODMAN&RENSHAW upgraded PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th. HC Wainwright cut their target price on PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, December 26th. Finally, Craig Hallum initiated coverage on shares of PolyPid in a research note on Monday, November 4th. They issued a “buy” rating and a $10.00 price objective for the company.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.